Stockholm, Sweden

Magdalena Malm


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Magdalena Malm

Introduction

Magdalena Malm, an innovative inventor based in Stockholm, Sweden, has made significant contributions to the field of biotechnology. With a strong focus on human health, her work centers around the development of polypeptides that offer promising applications in imaging and therapeutic contexts.

Latest Patents

Malm holds a patent for HER3 binding polypeptides, which are designed to bind to the human epidermal growth factor receptor 3 (HER3). This patent outlines polypeptides that carry a unique HER3 binding motif, specifically the amino acid sequence EKYXAYXEIW XLPNLTXXQXAAFIGXLXD (SEQ ID NO:110). The implications of this invention are substantial, as it opens avenues for advancements in both diagnostic imaging and targeted therapy for various diseases.

Career Highlights

Currently employed at Affibody AB, Malm has established herself as a key player in the biotechnology sector. Her work at Affibody highlights her expertise in developing therapeutic solutions that leverage cutting-edge technology to enhance treatment options for patients.

Collaborations

Throughout her career, Magdalena Malm has collaborated with notable colleagues, including John Löfblom and Stefan Ståhl. These collaborations have further enriched her work, combining diverse perspectives and expertise in the quest for innovative solutions in the healthcare arena.

Conclusion

Magdalena Malm's pioneering work in the development of HER3 binding polypeptides underscores her vital role in advancing biotechnological innovations. With her ongoing contributions to Affibody AB and collaboration with esteemed colleagues, she continues to push the boundaries of what is possible in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…